Current Opinion in Oncology最新文献_第3页

Skin cancer screening in solid organ transplant recipients: development of the SUNTRAC tool. 实体器官移植受者皮肤癌筛查：SUNTRAC工具的开发。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-03-01 Epub Date: 2026-02-04 DOI: 10.1097/CCO.0000000000001222

Wiam Al Bouzidi, Mariano Suppa, Veronique Del Marmol

{"title":"Skin cancer screening in solid organ transplant recipients: development of the SUNTRAC tool.","authors":"Wiam Al Bouzidi, Mariano Suppa, Veronique Del Marmol","doi":"10.1097/CCO.0000000000001222","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001222","url":null,"abstract":"Purpose of review: To summarize the development, validation, and current clinical use of the Skin and Ultraviolet Neoplasia Risk Assessment Calculator (SUNTRAC) tool. We also discuss key gaps, including the need for greater personalization, incorporation of additional risk factors, and clearer clinical protocols to support its integration into routine care.Recent findings: Skin cancer remains the most frequent malignancy in solid organ transplant recipients (SOTRs), driven by long-term immunosuppression and other patient-specific risk factors. The SUNTRAC tool was developed to stratify skin cancer risk in this population using five key variables: Caucasian ethnicity, prior history of skin cancer, older age at transplant, male sex, and thoracic organ transplantation. Based on these well established risk factors, patients are categorized into defined risk groups with tailored screening recommendations. Furthermore, large European studies have validated the SUNTRAC tool in diverse populations and extended its utility beyond squamous cell carcinoma to include basal cell carcinoma. Additional research has explored refinements to improve its accuracy and clinical applicability.Summary: The SUNTRAC tool is the most recent risk stratification model specifically designed to assess skin cancer risk in solid organ transplant recipients (SOTRs). Although international validation studies have demonstrated its utility across diverse populations, standardized guidelines for its clinical implementation remain lacking. Despite strong external validation and wide availability, SUNTRAC is still inconsistently implemented in transplant referral pathways and guideline-driven care, illustrating a persistent gap between evidence and routine practice.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 2","pages":"102-106"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Noninvasive skin imaging of melanocytic and nonmelanocytic tumours: recent findings. 黑素细胞和非黑素细胞肿瘤的无创皮肤成像：最新发现。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-03-01 Epub Date: 2026-02-02 DOI: 10.1097/CCO.0000000000001221

Lucas Boussingault, Lyna Mtimet, Mariano Suppa

{"title":"Noninvasive skin imaging of melanocytic and nonmelanocytic tumours: recent findings.","authors":"Lucas Boussingault, Lyna Mtimet, Mariano Suppa","doi":"10.1097/CCO.0000000000001221","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001221","url":null,"abstract":"Purpose of review: Early diagnosis of skin cancer is essential for patient care. Noninvasive skin imaging devices have become increasingly used for the assessment of melanoma and nonmelanoma skin cancers (NMSC). This article reviews the scientific literature published from March 2024 up to October 2025 and highlights the latest findings.Recent findings: Reflectance confocal microscopy remains the technique of choice for melanoma and lentigo maligna as it enhances diagnosis and reduces unnecessary biopsies. Line-field confocal optical coherence tomography confirms its utility for NMSC but shows growing potential for melanocytic lesions. Optical coherence tomography and high-frequency ultrasound provide evaluation of tumour thickness and margins. Dermoscopy and its high-magnification variant still serve as more accessible tools. Moreover, the addition of artificial intelligence and tele-imaging platforms is emerging.Summary: Noninvasive skin imaging devices, combined with artificial intelligence, are useful throughout patient management as they improve diagnosis, treatment monitoring, and surgical planning. They reduce unnecessary biopsies, aim towards more personalized medicine and overall improve patient care.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 2","pages":"95-101"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global priorities for advancing cancer survivorship. 促进癌症生存的全球优先事项。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-03-01 Epub Date: 2026-02-02 DOI: 10.1097/CCO.0000000000001217

Henry C Y Wong, Nicolas H Hart, Alexandre Chan, Carolyn Ee, Carla Thamm, Raymond J Chan

{"title":"Global priorities for advancing cancer survivorship.","authors":"Henry C Y Wong, Nicolas H Hart, Alexandre Chan, Carolyn Ee, Carla Thamm, Raymond J Chan","doi":"10.1097/CCO.0000000000001217","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001217","url":null,"abstract":"Purpose of review: Cancer survivorship is increasingly recognized as an important component of cancer care, yet access to high-quality care remains inconsistent globally. This review highlights priorities for advancing survivorship care worldwide, focusing on equity of access, outcomes for vulnerable populations, multidisciplinary models, technology-enabled interventions, and global collaboration.Recent findings: Survivorship needs differ across tumor streams and cancer sub-populations, especially older adults, adolescent, and people with advanced or metastatic cancers who face unique physical, psychosocial, and other practical challenges. Models that involve a variety of clinicians, such as oncologists and hematologists, primary care providers, nurses and allied health providers maintain quality of life, reduce healthcare costs, and support patient preferences, yet most countries still rely on oncologist-led follow-up. Digital health and artificial intelligence have the potential to enhance symptom monitoring, improve patient engagement, and deliver personalized care. Surveys led by the International Psycho-Oncology Society (IPOS) and Multinational Association of Supportive Care in Cancer (MASCC) reveal persistent disparities, particularly in low-income and middle-income countries and communities, highlighting evident gaps in supportive care access, infrastructure, and guideline implementation.Summary: Advancing high-quality survivorship care requires embedding equity into research and policy, expanding multidisciplinary and technology-enabled care models, and strengthening global collaboration. Longitudinal studies, region-specific guidelines, and capacity building in low-resource and middle-resource settings are essential. Implementing these strategies can optimize the outcomes and ensure sustainable care delivery for cancer survivors worldwide.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 2","pages":"137-145"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melanoma in adolescents and young adults: special considerations. 青少年和年轻人的黑色素瘤：特殊考虑。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-03-01 Epub Date: 2026-01-29 DOI: 10.1097/CCO.0000000000001220

Sofie Abboud, Luigi Romano, Mireille Langouo Fontsa

{"title":"Melanoma in adolescents and young adults: special considerations.","authors":"Sofie Abboud, Luigi Romano, Mireille Langouo Fontsa","doi":"10.1097/CCO.0000000000001220","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001220","url":null,"abstract":"Purpose of review: Melanoma in adolescents and young adults (AYAs, 15-39 years) occupies a unique position between pediatric and adult disease. Although uncommon, it represents a meaningful proportion of malignancies in this age group. Its distinct epidemiology, histopathological subtypes, and clinical features necessitate age-specific approaches. This review synthesizes current evidence to clarify the unique characteristics of AYA melanoma and to inform future research and clinical practice.Recent findings: Emerging data reveal notable age- and sex-specific differences in anatomical distribution, stage at presentation, and molecular alterations. AYAs more often present with superficial spreading and Spitzoid melanomas, frequently driven by BRAF, NRAS, or kinase fusions. Genetic susceptibility often interacts with ultraviolet exposure and tanning behaviors. Management generally follows adult protocols, including conservative surgery, sentinel lymph node biopsy, and systemic immunotherapy or targeted therapies for advanced disease. Overall survival is favorable compared with older adults, though male patients consistently have worse outcomes. Survivors face an increased risk of second primary melanomas, highlighting the need for long-term surveillance. Psychosocial and reproductive health issues are increasingly recognized as essential components of care.Summary: AYA melanoma requires tailored, multidisciplinary strategies that integrate prevention, molecular profiling, long-term follow-up, and dedicated research frameworks to optimize clinical outcomes.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 2","pages":"89-94"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supportive care in the world: an international opinion on MASCC's perspectives. 世界上的支持性护理：MASCC视角下的国际观点。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-03-01 Epub Date: 2026-02-05 DOI: 10.1097/CCO.0000000000001218

Fatma Ben Abid, Mounir Bachouchi, Corina Van Den Hurk, Andrea Antonuzzo, Amine Souadka

{"title":"Supportive care in the world: an international opinion on MASCC's perspectives.","authors":"Fatma Ben Abid, Mounir Bachouchi, Corina Van Den Hurk, Andrea Antonuzzo, Amine Souadka","doi":"10.1097/CCO.0000000000001218","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001218","url":null,"abstract":"Purpose of review: Supportive care is no longer a secondary aspect of oncology; it is the foundation that enables people with cancer not only to survive but to live with dignity, comfort, and relief throughout and beyond treatment. In 2025, as cancer survival improves globally, the need to integrate supportive care as a universal standard has become increasingly urgent. This review is timely and relevant as it examines the current global landscape of supportive care and the persisting inequities that threaten its implementation across health systems.Recent findings: Over the past three and a half decades, the Multinational Association of Supportive Care in Cancer (MASCC) has been central to the evolution of the field by advancing research, developing evidence-based guidelines, training health care professionals, and amplifying the voices of patients and caregivers. Despite this progress, major disparities remain. High-income countries increasingly embed supportive care within standard oncology practice, while many low- and middle-income countries face limited access to essential medicines, trained staff, and survivorship programs.Summary: This commentary reflects an international perspective on where supportive care stands and where it must go. It highlights MASCC's contributions and future vision through its Study Groups, Centers of Excellence, and the Supportive Care 2030 Movement, a global roadmap for equity, universal access, and improved patient-reported outcomes. Supportive care is not optional; it is a right and a prerequisite for quality cancer care and survivorship, requiring sustained innovation, inclusivity, and global commitment.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"38 2","pages":"114-119"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving landscape of bispecific antibodies in the treatment of lung cancer. 双特异性抗体在肺癌治疗中的发展前景。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-01-01 Epub Date: 2025-11-07 DOI: 10.1097/CCO.0000000000001206

Xuanhong Jin, Chang Chang, Fei Zhou

{"title":"The evolving landscape of bispecific antibodies in the treatment of lung cancer.","authors":"Xuanhong Jin, Chang Chang, Fei Zhou","doi":"10.1097/CCO.0000000000001206","DOIUrl":"10.1097/CCO.0000000000001206","url":null,"abstract":"Purpose of review: Lung cancer, the leading cause of cancer mortality, faces persistent challenges like resistance to targeted therapy and immunotherapy. This review comprehensively outlines the evolving role of bispecific antibodies (bsAbs), summarizing their mechanisms, clinical findings, and future directions. It is timely given emerging data and novel bsAbs that may reshape lung cancer treatment.Recent findings: The article covers the development and clinical application of bsAbs in lung cancer, highlighting advancements in production technology and diverse formats. bsAbs are designed to simultaneously bind two different antigens, enabling mechanisms such as immune cell bridging and dual targeting of oncogenic pathways. Key themes include the use of bsAbs as first-line treatments, their role in second-line and later-line settings, and their application in neoadjuvant or adjuvant therapy.Summary: The findings suggest that bsAbs represent a significant advancement in lung cancer treatment, offering new therapeutic strategies to address unmet needs. The development of next-generation bsAbs, including trispecific antibodies and conditional activation platforms, promises enhanced precision and safety. These innovations have the potential to improve outcomes for patients with advanced lung cancer. Future research should focus on optimizing patient selection through biomarker-driven approaches and exploring combination therapies to maximize the benefits of bsAbs.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"54-70"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145495064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibody-drug conjugates in lung cancer: current landscape and future perspectives. 抗体-药物结合物在肺癌中的应用：现状和未来展望。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-01-01 Epub Date: 2025-10-22 DOI: 10.1097/CCO.0000000000001200

Xinru Chen, Caicun Zhou

{"title":"Antibody-drug conjugates in lung cancer: current landscape and future perspectives.","authors":"Xinru Chen, Caicun Zhou","doi":"10.1097/CCO.0000000000001200","DOIUrl":"10.1097/CCO.0000000000001200","url":null,"abstract":"Purpose of review: Antibody-drug conjugates (ADCs) have emerged as a significant therapeutic class in lung cancer, integrating the target specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. This review delineates ADC structure, mechanisms of action, and clinical advancements in nonsmall-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), with a focus on novel bispecific formats to address tumor heterogeneity and therapeutic approaches to overcome resistance mechanisms.Recent findings: Multiple ADCs have demonstrated significant clinical activity in biomarker-defined patient subsets. The human epidermal growth factor receptor 2 (HER2)-targeted ADC trastuzumab deruxtecan has demonstrated unprecedented efficacy in HER2 -mutant NSCLC, resulting in global regulatory approvals. Novel ADC targets such as TROP2, HER3, MET, CEACAM5, integrin β6, DLL3, B7-H3, and SEZ6 are undergoing clinical evaluation. Advancements in payload design, linker stability, and conjugation methodologies have enhanced therapeutic indices. Concurrently, bispecific ADCs are emerging to address challenges posed by intratumoral heterogeneity and antigen-loss-mediated resistance mechanisms.Summary: ADCs are transforming lung cancer therapy by delivering potent cytotoxics with manageable safety. Next-generation bispecific and biparatopic formats may broaden eligibility, improve tumor penetration, and delay resistance. Incorporating predictive biomarkers and real-time monitoring will be key to their use in earlier disease and to establishing ADCs as a cornerstone of precision oncology.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"71-82"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145495004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic therapy of nonsmall cell lung cancer: breakthroughs during the last five decades. 非小细胞肺癌的全身治疗：过去五十年的突破。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-01-01 Epub Date: 2025-10-22 DOI: 10.1097/CCO.0000000000001201

Robert Pirker, Caicun Zhou

引用次数: 0

Treatment of lung cancer in pregnant women. 孕妇肺癌的治疗。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-01-01 Epub Date: 2025-10-08 DOI: 10.1097/CCO.0000000000001198

Martin Svaton

{"title":"Treatment of lung cancer in pregnant women.","authors":"Martin Svaton","doi":"10.1097/CCO.0000000000001198","DOIUrl":"10.1097/CCO.0000000000001198","url":null,"abstract":"Purpose of review: Lung cancer in pregnancy is relatively rare, however, with increasing gestational age, its incidence is likely to increase. Many of the summary recommendations were developed before the advent of targeted therapies and immunotherapy, which represent a significant part of modern lung cancer treatment. The aim of this review is therefore to provide a current perspective on this issue.Recent findings: In diagnostics, we are replacing PET/computed tomography with MRI. It is necessary to discuss with the patient sensitively whether to continue the pregnancy and if so, whether to choose treatment and what kind. Case reports are described about practically all treatment procedures generally known for lung cancer, but some of them cannot be recommended due to possible risks (bevacizumab, chest irradiation), other should be chosen with great caution (some targeted therapy, immunotherapy). Chemotherapy appears to be relatively safe outside the first trimester of pregnancy. The review also addresses general principles of neonatal delivery in these patients.Summary: Lung cancer in pregnancy is highly stressful for both the pregnant woman and the treatment team. The benefits and risks of possible treatment options need to be openly discussed and a consensus reached between the patient and the treatment team.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"47-53"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small cell lung cancer transdifferentiation: not a negligible phenomenon. 小细胞肺癌转分化：不可忽视的现象。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-01-01 Epub Date: 2025-11-20 DOI: 10.1097/CCO.0000000000001205

Lilla Horvath, Kristiina Boettiger, Zsolt Megyesfalvi, Balázs Döme, Clemens Aigner, Anita Horváth-Rózsás, Judit Berta

{"title":"Small cell lung cancer transdifferentiation: not a negligible phenomenon.","authors":"Lilla Horvath, Kristiina Boettiger, Zsolt Megyesfalvi, Balázs Döme, Clemens Aigner, Anita Horváth-Rózsás, Judit Berta","doi":"10.1097/CCO.0000000000001205","DOIUrl":"10.1097/CCO.0000000000001205","url":null,"abstract":"Purpose of review: Small cell lung cancer (SCLC), particularly its transdifferentiated form, is highly aggressive and has a poor prognosis. The diagnosis of SCLC transdifferentiation is challenging, as repeat biopsies are often not clinically feasible and few noninvasive predictors of this neuroendocrine transformation have been identified to date.Recent findings: Some retrospective studies and case reports have investigated this phenomenon. These studies indicate that it can occur in non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, or rearranged during transfection (RET) fusions, typically following treatment with tyrosine kinase inhibitors. However, it has also been observed in cases of EGFR-wild type NSCLC after immunotherapy or radiation therapy.Summary: Several molecular mechanisms that can drive SCLC transdifferentiation have been identified. The treatment of transdifferentiated SCLC remains a significant challenge, although promising new strategies are currently under investigation. This review summarizes the current understanding of SCLC transdifferentiation.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"39-46"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0